Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

NCT03201250 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
11
Enrollment
OTHER
Sponsor class

Stopped Phase I response to treatment was not as expected and the myeloma field in treatment has changed since initiating the study, so investigators felt the study should not be pursued into Phase II.

Conditions

Interventions

Sponsor

University of Nebraska

Collaborators